Pell Bio-Med Technology Co., Ltd. (TWSE: 6949)
Health Care · Biotechnology · TW
NT$46.85
+5.28% today · +140.9% 1Y
Pell Bio-Med Technology Co., Ltd. (TWSE: 6949) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.92B and employs 94 people.
Over the last twelve months the share price has gained 140.9%, trading between 15.43 and 81.90.
Tweenvest scores Pell Bio-Med Technology Co., Ltd. across four factors: quality 48/100, value 91/100. Its strongest factor is value.
6949 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.92B
- Revenue (TTM)
- $909.26K
- P/E
- —
- EPS
- -0.35
- Dividend yield
- —
- Beta (5Y)
- 1.33
- 52-week high
- NT$81.90
- 52-week low
- NT$15.43
- Avg volume (3M)
- —
- Shares outstanding
- 1.31B
- Employees
- 94
- Next earnings
- —
About Pell Bio-Med Technology Co., Ltd.
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.
- ISIN
- TW0006949001
- Founded
- 2017
- Listed since
- Mar 8, 2024
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ADARx Pharmaceuticals, Inc.NasdaqGS: ADRX | $1.99B | $17.78 | 0.00% |
| OliX Pharmaceuticals, IncKOSDAQ: A226950 | $1.99B | ₩117,300.00 | +0.43% |
| Vir Biotechnology, Inc.NasdaqGS: VIR | $1.98B | $11.36 | -2.91% |
| Jinyu Bio-technology Co., Ltd.SHSE: 600201 | $1.93B | CN¥11.84 | +1.98% |
| Lakefront Biotherapeutics NVENXTAM: LKFT | $1.92B | €26.32 | +1.70% |
| Agios Pharmaceuticals, Inc.NasdaqGS: AGIO | $1.90B | $31.10 | -2.23% |
| Sarepta Therapeutics, Inc.NasdaqGS: SRPT | $1.89B | $17.56 | -1.62% |
| Voronoi, Inc.KOSDAQ: A310210 | $1.87B | ₩138,400.00 | -3.96% |
Figures last refreshed Oct 11, 2026.